Pharmacogenetic typing for oral anti-coagulant response among factor V Leiden mutation carriers

Conclusions: Pre-prescription genotyping for coumarin drugs, if introduced in Indians with inherited thrombophilia (in whom oral anti-coagulant therapy may be necessary), is likely to identify 9.7% (hypersensitive) subjects in whom the optimum anti-coagulation may be achieved with reduced dosages, 44.3% (normal sensitivity) who may require higher dose and also 55.6% (hyper and moderate sensitivity) subjects who are likely to experience bleeding episodes.
Source: Indian Journal of Human Genetics - Category: Genetics & Stem Cells Authors: Source Type: research